Cytyc ThinPrep Pap Test Distribution Helps Boost Stock 137% In 1999
This article was originally published in The Gray Sheet
Executive Summary
Increasing availability of Cytyc's ThinPrep Pap test product through added laboratory contracts, coupled with an improved reimbursement environment and strong fundamentals, set the stage for a 137.1% run up of the cervical cytology firm's stock in 1999. The issue closed at 61-1/16, up 35-5/16 for the year.